Biotechnology

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).

Immuno-oncology company Portage Biotech to evaluate strategic alternatives

Clinical-stage immuno-oncology company Portage Biotech has announced plans to expand its assessment of strategic alternatives.

AGC completes facility expansion for pDNA and mRNA production line

AGC Biologics has completed the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at Heidelberg, Germany.

Chinese biotech firm Therorna closes $42m Series A financing round

China-based biotech company Therorna has secured $42m in a Series A financing round to support its growth and fuel product pipeline development.

Inceptor Bio raises $37m from Series A to advance CAR-T lead programme

Biotechnology firm Inceptor Bio has raised $37m from Series A funding round that was led by Kineticos Ventures.

Arbor Biotechnologies raises $215m through Series B round

Massachusetts-based Arbor Biotechnologies has raised $215m through Series B financing round, and plans to use the proceeds to advance its next-generation precision editing therapeutics.

Prime Medicine launches with $315m funding to advance Prime Editing platform

Biotechnology company Prime Medicine has launched with $315m funding to advance its Prime Editing platform, a next-generation gene editing technology.

NIAID grants $2.5m to 12 institutes for bacteriophage therapy research

A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.

Akron Biotech to exclusively manufacture Human AB Serum for Octapharma

Akron Biotechnology (Akron Biotech) has signed an exclusive global agreement with Swiss-based Octapharma, to manufacture virally inactivated Human AB Serum for the cell therapy market.